Effect of treatment with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) or 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC-409962) plus vincristine (NSC-67574) on lymphocyte reactivity of melanoma patients

Abstract

Fourteen patients with surgically incurable malignant melanoma treated with dimethyl triazeno imidazole carboxamide (DTIC) (2 mg/kg/day i.v. × 10) and 18 patients treated with the combination of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) (150 mg/m2 i.v.) plus vincristine (2 mg/m2 i.v.) on day 1 only, were tested for lymphocyte reactivity against melanoma cells before and after treatment. Neither chemotherapeutic regimen regularly affected lymphocyte reactivity, either in the presence of fetal calf serum or in the presence of the patients' autologous serum when tested 1 month after treatment. Three patients receiving repeated DTIC therapy and six patients receiving repeated BCNU plus vincristine therapy exhibited little variation in lymphocyte reactivity throughout the course of treatment.